Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Public ClinicalTrials.gov record NCT03298451. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Study identification
- NCT ID
- NCT03298451
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 1,324 participants
Conditions and interventions
Conditions
Interventions
- Durvalumab Drug
- Durvalumab (Regimen 1) Drug
- Durvalumab (Regimen 2) Drug
- Sorafenib Drug
- Tremelimumab (Regimen 1) Drug
- Tremelimumab (Regimen 2) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 10, 2017
- Primary completion
- Aug 26, 2021
- Completion
- Aug 26, 2026
- Last update posted
- Mar 19, 2026
2017 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Los Angeles | California | 90048 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | San Francisco | California | 94158 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Fort Myers | Florida | 33916 | — |
| Research Site | Jacksonville | Florida | 32224 | — |
| Research Site | Westwood | Kansas | 66205 | — |
| Research Site | Baltimore | Maryland | 21231 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Charlotte | North Carolina | 28262 | — |
| Research Site | Portland | Oregon | 97213 | — |
| Research Site | Pittsburgh | Pennsylvania | 15237 | — |
| Research Site | Dallas | Texas | 74235 | — |
| Research Site | Dallas | Texas | 75216 | — |
| Research Site | Dallas | Texas | 75235 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Houston | Texas | 77090 | — |
| Research Site | Murray | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 140 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03298451, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 19, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03298451 live on ClinicalTrials.gov.